Análisis de la expresión del antígeno nuclear de proliferación celular (PCNA) en 24 carcinomas primarios de pulmón de células no pequeñas y correlación con la supervivencia | Archivos de Bronconeumología

Subscribe to this journal

Advanced Search

Share

Enter your user name and password

* Required fields

Enter your email address

March 1996 Análisis de la expresión del antígeno nuclear de proliferación celular (PCNA) en...

Archivos de Bronconeumología

ISSN: 0300-2896

Archivos de Bronconeumologia is a scientific journal that preferentially publishes prospective original research articles whose content is based upon results dealing with several aspects of respiratory diseases such as epidemiology, pathophysiology, clinics, surgery, and basic investigation. Other types of articles such as reviews, editorials, a few special articles of interest to the society and the editorial board, scientific letters, letters to the Editor, and clinical images are also published in the Journal. It is a monthly Journal that publishes a total of 12 issues and a few supplements, which contain articles belonging to the different sections.

All the manuscripts received in the Journal are evaluated by the Editors and sent to expert peer-review while handled by the Editor and/or an Associate Editor from the team. The Journal is published monthly in English.

Manuscripts will be submitted electronically using the following web site: https://www.editorialmanager.com/ARBR/, link which is also accessible through the main web page of Archivos de Bronconeumologia.

Access to any published article, is possible through the Journal's web page as well as from PubMed, Science Direct, and other international databases. Furthermore, the Journal is also present in Twitter and Facebook. The Journal expresses the voice of the Spanish Respiratory Society of Pulmonology and Thoracic Surgery (SEPAR) as well as that of other scientific societies such as the Latin American Thoracic Society (ALAT) and the Iberian American Association of Thoracic Surgery (AICT).

Authors are also welcome to submit their articles to the Journal's open access companion title, Open Respiratory Archives.

See more

Archivos de Bronconeumologia has received the new Impact Factor (JCR). The impact factor has risen from 6.333 in 2021 to 8 in the last evaluated year, 2022.
It is needed to be a member of SEPAR or have a subscription to access full texts of articles published last year. Abstracts are available for all visitors.

Indexed in:

Current Contents/Clinical Medicine, JCR SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, IBECS

See more

Follow us:

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

See more

Impact factor 2022

8

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2022

2.8

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2022

0.434

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2022

0.437

View more metrics

Open Access Option

Journal Information

Previous article | Next article

Vol. 32. Issue 3.

Pages 127-131 (March 1996)

Export reference

Share

Share

More article options

Vol. 32. Issue 3.

Pages 127-131 (March 1996)

DOI: 10.1016/S0300-2896(15)30798-5

Full text access

Análisis de la expresión del antígeno nuclear de proliferación celular (PCNA) en 24 carcinomas primarios de pulmón de células no pequeñas y correlación con la supervivencia

Analysis of proliferating cell nuclear antigen expression in 24 cases of primary non-small cell lung cancer and correlation with survival

Visits

9293

Download PDF

V.M. Castellano1, T. Sotelo, C. Ballestín

Departamento de Anatomía Patológica. Hospital Universitario 12 de Octubre. Madrid

A. López-Encuentra*, G. Varela**

* Servicio de Neumología. Hospital Universitario 12 de Octubre. Madrid

** Servicio de Cirugía Torácica. Hospital Universitario 12 de Octubre. Madrid

This item has received

Article information

Abstract

Bibliography

El antígeno nuclear de proliferación celular (PCNA) o ciclina es una proteína nuclear de 36 kD que está involucrada en la replicación del ADN celular y es considerada como un índice de proliferación en algunas neoplasias. Este trabajo analiza la expresión de PCNA en 24 carcinomas primarios de pulmón de células no pequeñas empleando el anticuerpo monoclonal PC-10 en material procesado en parafina. Encontramos importantes variaciones inter e intratumorales en la expresión de PCNA. No observamos relación estadísticamente significativa entre la cantidad de PCNA expresada y el tamaño y localización tumoral, índice mitósico, tipo histológico del tumor y edad del paciente. Estudiamos la supervivencia en los pacientes en 19 casos con el propósito de correlacionarla con la expresión de PCNA, obteniendo una relación estadísticamente significativa (r=0,47; p < 0,05) entre la cantidad de PCNA expresada y la supervivencia en los casos incluidos en nuestro estudio, pero al establecer un sistema de graduación de la expresión de PCNA en tres grados -leve (0-25%), moderado (25-50%) e intenso (> 50%)- no encontramos diferencias estadísticamente significativas entre las supervivencias ni un valor pronóstico en la graduación de PCNA.

Palabras clave:

Cáncer de pulmón

Antígeno nuclear de proliferación celular (PCNA)

Ciclina

Supervivencia

Factor pronóstico

Immunohistoquímica

Proliferating cell nuclear antigen (PCNA) is a 36kD nuclear protein involved in DNA replication that is believed to provide an indication of proliferation in some neoplasms. This study analyzes PCNA expression in 24 cases of primary non-small cell lung cancer using monoclonal PC-10 antibodies in paraffin embedded material. We found significant inter and intra-tumoral variations in PCNA expression, and no statistically significant relation between the amount of PCNA expression and the size and location of tumors, index of mitosis, histological tumor type or patient age. We found a statistically significant relation (r=0.47; p < 0.05) between survival and amount of PCNA expression in a sample of 19 cases, but no statistically significant differences in survival related to whether PCNA expression was slight (0-25), moderate (25%-50%) or high (> 50%), and no prognostic value for degree of PCNA expression.

Key words:

Lung cancer

Proliferating cell nuclear antigen

PCNA

Cyclin

Survival

Prognostic factor

Immunohistochemistry

Full text is only aviable in PDF

Bibliografía

K. Miyachi, M.J. Frilzlcr, E.M. Tan.

An auloantibody to a nuclear antigen in proliferating cells.

J Immunol, 121 (1978), pp. 2.228-2.234

R. Bravo, J.E. Celis.

A search for differential polypeptide synthesis throughout the cell cycle of Hela cells.

J Cell Biol, 84 (1980), pp. 795-802

M.B. Mathews, R.M. Bernstein, B.R. Franza, J.I. Garrels.

The identity of the proliferating cell nuclear antigen and cvclin.

Nature, 309 (1984), pp. 374-376

Y. Takasaki, D. Fischwild, E.M. Tan.

Characterization of proliferating cell nuclear antigen recognized hy autoantibodies in lupus sera.

J Exp Med, 159 (1984), pp. 981-992

J.E. Celis, A. Celis.

Cell cycle dependent variations in the distribution of the nuclear antigen in cultured celis: subdivision of S phase.

Proc Natl Acad Sci USA, 82 (1985), pp. 143-157

D. Jaskulski, J.K. De Riel, W.E. Mercer, B. Calabretta, R. Baserga.

(Inhibition of cellular proliferation by antisence oligodeoxynucleotides to PC NA cyclin.

Science, 240 (1988), pp. 1.544-1.546

http://dx.doi.org/10.1126/science.240.4860.1767 | Medline

M. Zuber, E.M. Tan, M. Ryoji.

Involvement of proliferating cell nuclear antigen (cvclin) in DNA replication in living cells.

Mol Cell Biol, 9 (1989), pp. 57-66

C.K. Tan, C. Castillo, A.G. So, K.M. Downey.

An auxiliary protein for DNA polymerase-delta from foetal calf thymus.

J Biol Chem, 261 (1986), pp. 12.310-12.316

R. Bravo, R. Fratik, P.A. Blundell, H. MacDonald-Bravo.

Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Nature, 326 (1987), pp. 515-517

http://dx.doi.org/10.1038/326515a0 | Medline

G. Prelich, C.K. Tan, M. Kostura, M.B. Mathews, Ag. So, K.M. Downey, B. Stillman.

Functional identity of proliferaiing cell nuclear antigen and a DNA polymerase-delta auxilliary protein.

Nature, 326 (1987), pp. 517-520

http://dx.doi.org/10.1038/326517a0 | Medline

B.A. Robbins, D. De la Vega, K. Ogata, E.M. Tan, R. Nakamura.

lmmunohistochemical detection of proliferating cell nuclear antigen in solid human malignances.

Arch Pathol Lab Med, 111 (1987), pp. 841-845

P.A. Hall, D.A. Levison, A.L. Woods, C.C.W. Yu, D.B. Kelloek, J.A. Watkins, D.M. Bames, C.E. Gillet, R. Camplejohn, R. Dorel, N.H. Waseen, D.P. Lane.

Proliferaiing cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.

J Pathol, 162 (1990), pp. 285-294

http://dx.doi.org/10.1002/path.1711620403 | Medline

P.H.M.H. Theunissen, M.P.G. Leers, E.C.M. Bollen.

Proliferating cell nuclear antigen (PCNA) expresion in formalin-fixed tissue of non-small cell lung carcinoma.

Hislopathology, 20 (1992), pp. 251-255

F.A. Carey, G. Fabbroni, D. Lamb.

Expression of proliferating cell nuclear antigen in lung cancer: a systematic study and correlation with DNA ploidy.

Hislopathology, 20 (1992), pp. 499-503

G. Fontanini, P. Macchiarini, S. Pepe, A. Ruggiero, M.J. Hardin, D. Bigini, S. Vignati, R. Pingitore, C.A. Ageletti.

The expression of proliferating cell nuclear antigen in paraffin sections of peripheral. node-negative non-small cell lung cancer.

Cancer, 70 (1992), pp. 1.520-1.527

Macchiarini P, Fontanini G, Hardin MJ. Chuanchich H. Bigini D. Vignati S. Pingitore R. Angcletti A. Blood vessel invasion by tumor cells predicts recurrence in completely resected TI N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 199; 106: 80-89.

J.I. Ogawa, T. Tsurumi, S. Yamada, S. Koide, A. Shohtsu.

Blood vessel invasion and expression of sialyl Lewis and proliferating cell nuclear antigen in stage I non-small cell lung cancer.

Cancer, 73 (1994), pp. 1.177-1.183

J.I. Ogawa, M. Iwazaki, H. Inoue, S. Koide, A. Shohtsu.

Immunohistochemical study of glutatione-related enzymes and proliferative antigens in lung cancer. Relation to cisplatin sensitivitv.

Cancer, 71 (1993), pp. 2.204-2.209

R.L. García, M.D. Coltrera, A.M. Gown.

Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fi.xed, embedded tissues.

Ani J Pathol, 134 (1989), pp. 733-739

M. Fujii, M. Motoi, H. Saeki, K. Aoe, S. Moriwaki.

Prognoslic significance of proliferating cell nuclear antigen (PCNA) expression in non-small cell lung cancer.

Acta Med Okayama, 4 (1993), pp. 103-108

M. Ebina, S.M. Sleinberg, J.L. Mulshine, R.I. Linnoila.

Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer.

Cancer Res, 54 (1994), pp. 2.496-2.503

T. Ishida, S. Kaneko, K. Akazawa, M. Tateishi, K. Sugio, K. Sugimachi.

Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients.

Cancer Res, 53 (1993), pp. 5.000-5.003

G. Fontanini, S. Vignati, D. Bigini, G.R. Merlo, A. Rihccchini, C.A. Angeletti, et al.

Human non-small cell lung cancer: p53 protein acumulation is an carly event and persists during metastatic progression.

J Pathol, 174 (1994), pp. 23-31

http://dx.doi.org/10.1002/path.1711740105 | Medline

T. Kawai, M. Suzuki, S. Kono, N. Shinomiya, M. Rokutanda, K. Tagaki, et al.

Proliferating cell nuclear aniigen and Ki-67 in lung carcinoma. Correlation wilh DNA flow cytometric analysis.

Cancer, 74 (1994), pp. 2.468-2.473

R. Bravo, H. MacDonald-Bravo.

Existence of two populalions of cyclin/proliferating cell nuclear antigen during the cell cyle: association with DNA replication siles.

J Cell Biol, 108 (1987), pp. 1.549-1.854

C.D. Chang, L. Ottavio, S. Travalli, Ke. Lipson, R. Baserga.

Transcriplional and posttranscriptional regulation of mRNA levels of the proliferating cell nuclear antigen gene.

Mol Cell Biol, 10 (1990), pp. 3.289-3.296

J.M. Almendral, D. Huebsch, P.A. Blundell, H. MacDonald-Bravo, R. Bravo.

Cloning and sequence of the human nuclear protein cyclin: homology with DNA binding proteins.

Proc Natl Acad Sci USA, 84 (1987), pp. 1.575-1.579

N.H. Waseem, D.P. Lane.

Monoclonal antibody analysis of the pro liferating cell nuclear antigen (PCNA). Struclural conservation and the delection of a nucleolar form.

J Cell Sci, 96 (1990), pp. 121-129

K. Ogata, P. Kurki, J.E. Celis, R.M. Nakamura, E.M. Tan.

Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication.

Exp Cell Res, 168 (1987), pp. 475-486

A.L. Woods, P.A. Hall, N.A. Shepherd, A.M. Handy, N.H. Weseem, D.P. Lane, et al.

The assessment of proliferating cell nuclear antigen (PCNA) iminunostaning in primare gastrointestinal lymphomas and its relationship to histological grade. S+G2+M phase fraction flow cylometric analysis) and prognosis.

Histopathology, 19 (1991), pp. 21-27

C.C.W. Yu, P.A. Hall, C.D.M. Fletcher, R.S. Camplejohn, N.H. Weseem, D.P. Lane, et al.

Haemangiopericytoma: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA).

Histopathology, 19 (1991),

Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica

Archivos de Bronconeumología

Article options

Tools